Natco Pharma shares plunged after the company reported a steep fall in fourth-quarter profit, revenue and EBITDA. Weak operating margins and lower annual earnings weighed on investor sentiment despite a one-time tax-related benefit recorded during the quarter and full financial year.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets